A bovine lactoferricin-lactoferrampin-encoding Lactobacillus reuteri CO21 regulates the intestinal mucosal immunity and enhances the protection of piglets against enterotoxigenic Escherichia coli K88 challenge

Weichun Xie, Liying Song, Xueying Wang, Yigang Xu, Zengsu Liu, Dongfang Zhao, Shubo Wang, Xiaolong Fan, Zhaorui Wang, Chong Gao, Xiaona Wang, Li Wang, Xinyuan Qiao, Han Zhou, Wen Cui, Yanping Jiang, Yijing Li, Lijie TangGut 2021 · DOI

TL;DR

This study engineered a probiotic Lactobacillus reuteri strain to produce a bovine antimicrobial peptide (LFCA), demonstrating its ability to protect piglets against ETEC infection. The engineered probiotic enhances intestinal barrier function, modulates gut microbiota, and boosts the immune response, offering a promising therapeutic strategy for intestinal inflammation.

What Problem Does This Paper Address?

Enterotoxigenic Escherichia coli (ETEC) is a major cause of diarrhea in humans and animals, particularly in developing nations, leading to significant health and economic burdens. While probiotics are known to support gut health, finding strains with multiple beneficial properties and understanding their precise mechanisms of action remains a challenge. This paper addresses the need for effective interventions against ETEC-induced diarrhea by investigating a novel approach: using a genetically engineered probiotic (Lactobacillus reuteri CO21) to deliver a potent antimicrobial peptide (bovine lactoferricin-lactoferrampin, LFCA) directly to the gut. The goal is to enhance intestinal immunity and barrier function, thereby protecting against ETEC infection.

Methods

The researchers engineered Lactobacillus reuteri CO21 to express and secrete LFCA, creating the recombinant strain LR-LFCA. They used a piglet model, chosen for its physiological similarity to humans, to evaluate the effects of oral LR-LFCA administration.

Key techniques employed include:

  • Bacterial Engineering: Constructing a plasmid to express LFCA in L. reuteri CO21.
  • In Vivo Studies: Administering LR-LFCA to neonatal piglets and subsequently challenging them with ETEC K88.
  • Gut Microbiota Analysis: Using 16S rRNA gene sequencing to assess changes in cecal microbiota composition and diversity.
  • Intestinal Morphology and Barrier Function Assessment:
    • Histological analysis (H&E staining) to examine villus height and crypt depth.
  • Western blotting and RT-qPCR to measure the expression of tight junction proteins (ZO-1, Claudin-2).
  • Measuring serum D-lactic acid and endotoxin levels as indicators of barrier integrity.
  • Immune Response Evaluation: ELISA to quantify pro-inflammatory and anti-inflammatory cytokines (IL-1β, IL-12, IL-6, TNF-α, IL-10) and immunoglobulin levels (IgG, IgA).
  • Oxidative Stress Analysis: Measuring antioxidant enzyme activities (SOD, GSH-Px, CAT, T-AOC) and the expression of key antioxidant pathway proteins (Nrf2, HO-1).
  • In Vitro Studies: Using porcine intestinal epithelial cells (IPEC-J2) stimulated with LPS to investigate the molecular mechanisms underlying LFCA's effects on tight junctions, inflammation (NF-κB pathway), and oxidative stress (Nrf2/HO-1 pathway).
  • Flow Cytometry: Assessing dendritic cell (DC) maturation and T cell proliferation.

Datasets

Not explicitly discussed as datasets in the traditional machine learning sense. The study utilizes data generated from experiments involving:

  • L. reuteri strains isolated from piglet intestinal mucus.
  • Bacterial cultures of S. aureus, ETEC K88, P. multocida, and S. enteritidis.
  • Neonatal piglets (Duroc × Large White × Landrace) as the animal model.
  • Porcine intestinal epithelial cells (IPEC-J2) for in vitro experiments.
  • 16S rRNA gene sequencing data from piglet cecal contents.

Key Insights and Ideas

  • Engineered Probiotic as a Delivery System: The study highlights the potential of using genetically modified probiotics like L. reuteri as effective vehicles for delivering therapeutic peptides directly to the gut, bypassing the need for costly peptide synthesis and purification.
  • Multi-faceted Protection: LR-LFCA doesn't just kill bacteria; it actively enhances the host's defenses by strengthening the intestinal barrier, modulating the gut microbiome, and dampening inflammatory responses. This holistic approach is crucial for combating complex infections like ETEC.
  • Targeting Key Signaling Pathways: The research delves into the molecular mechanisms, identifying that LFCA's effects on tight junctions are likely mediated through the MLCK pathway and its anti-inflammatory action involves inhibiting the NF-κB pathway. Furthermore, its antioxidant capacity is linked to the Nrf2/HO-1 pathway.
  • Piglet Model Relevance: The use of piglets, with their GI tract physiology closely mirroring humans, makes the findings highly relevant for both animal and human health applications.
  • Early Intervention is Key: The study emphasizes the benefits of early intervention with LR-LFCA, suggesting that introducing it shortly after birth can establish a healthier gut environment and improve resilience against pathogens.

Key Results

  • Colonization and Growth: LR-LFCA successfully colonized the piglets' intestines and improved growth performance (increased average daily gain).
  • ETEC Protection: Oral administration of LR-LFCA significantly attenuated ETEC K88-induced weight loss and reduced diarrhea incidence.
  • Enhanced Intestinal Barrier: LR-LFCA increased the expression of tight junction proteins (ZO-1 and Claudin-2) in the ileum, reduced serum D-lactic acid and endotoxin levels, and improved villus height and villus-to-crypt ratio.
  • Immune Modulation: LR-LFCA significantly increased serum IgG and intestinal IgA levels, and suppressed the production of pro-inflammatory cytokines (IL-1β, IL-12, IL-6, TNF-α) while increasing anti-inflammatory IL-10.
  • Gut Microbiota Improvement: LR-LFCA administration altered the gut microbiota composition, increasing beneficial Lactobacillus populations and decreasing potentially harmful bacteria like Escherichia-Shigella.
  • Antioxidant Capacity Boost: LR-LFCA enhanced antioxidant enzyme activities and upregulated Nrf2 and HO-1 expression, mitigating oxidative stress.
  • In Vitro Mechanism Confirmation: In IPEC-J2 cells, LFCA increased tight junction proteins, inhibited NF-κB signaling, and activated the Nrf2/HO-1 pathway, supporting the in vivo findings.

Limitations and Future Work

  • ETEC Strain Specificity: While effective against ETEC K88, the study doesn't explicitly state if LR-LFCA's protective effects extend to other ETEC strains or different pathogens.
  • Long-term Effects: The study primarily focuses on short-term effects. Long-term colonization and sustained benefits of LR-LFCA would be valuable to investigate.
  • Mechanism Complexity: While key pathways are identified, the intricate interplay of all mechanisms and potential off-target effects warrant further exploration.
  • Human Translation: While the piglet model is relevant, direct translation to human applications would require further clinical trials.

The authors suggest that future studies could explore the specific toxins involved in ETEC infection and how LR-LFCA counteracts them. They also propose LR-LFCA as a promising microecological agent for enhancing infant immunity and promoting optimal development, implying potential for broader applications beyond ETEC.

Summary updated

Abstract

Enterotoxigenic <i>Escherichia coli</i> (ETEC) is an important cause of diarrhea in human and animal. To determine the mechanism of a bovine lactoferricin-lactoferrampin (LFCA)-encoding <i>Lactobacillus reuteri</i> CO21 (LR-LFCA) to enhance the intestinal mucosal immunity, we used a newborn piglet intestine model to study the intestinal response to ETEC. Pigs were chosen due to the anatomical similarity between the porcine and the human intestine.4-day-old piglets were orally administered with LR-LFCA, LR-con (<i>L. reuteri</i> CO21 transformed with pPG612 plasmid) or phosphate buffered saline (PBS) for three consecutive days, within 21 days after these treatments, we found that LR-LFCA can colonize the intestines of piglets, improve the growth performance, enhance immune response and is beneficial for intestinal health of piglets by improving intestinal barrier function and modulating the composition of gut microbiota. Twenty-one days after, piglets were infected with ETEC K88 for 5 days, we found that oral administration of LR-LFCA to neonatal piglets attenuated ETEC-induced the weight loss of piglets and diarrhea incidence. LR-LFCA decreased the production of inflammatory factors and oxidative stress in intestinal mucosa of ETEC-infected piglets. Additionally, LR-LFCA increased the expression of tight junction proteins in the ileum of ETEC-infected piglets. Using LPS-induced porcine intestinal epithelial cells (IPEC-J2) <i>in vitro</i>, we demonstrated that LR-LFCA-mediated increases in the tight junction proteins might depend on the MLCK pathway; LR-LFCA might increase the anti-inflammatory ability by inhibiting the NF-κB pathway. We also found that LR-LFCA may enhance the antioxidant capacity of piglets by activating the Nrf2/HO-1 pathway. This study demonstrates that LR-LFCA is effective at maintaining intestinal epithelial integrity and host homeostasis as well as at repairing intestinal damage after ETEC infection and is thus a promising alternative therapeutic method for intestinal inflammation.
BibTeX
@inproceedings{xie2021bovine,
  author = {Weichun Xie and Liying Song and Xueying Wang and Yigang Xu and Zengsu Liu and Dongfang Zhao and Shubo Wang and Xiaolong Fan and Zhaorui Wang and Chong Gao and Xiaona Wang and Li Wang and Xinyuan Qiao and Han Zhou and Wen Cui and Yanping Jiang and Yijing Li and Lijie Tang},
  title = {{A bovine lactoferricin-lactoferrampin-encoding <i>Lactobacillus reuteri</i> CO21 regulates the intestinal mucosal immunity and enhances the protection of piglets against enterotoxigenic <i>Escherichia coli</i> K88 challenge}},
  booktitle = {Gut},
  year = {2021},
  doi = {10.1080/19490976.2021.1956281},
}
Figure